RemeGen Scales Back Private Placement to Fund New Drug R&D
RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan,...
China’s NMPA Suspends Daewoong Bio’s Antibiotic, Excludes Firm from National Procurement Program
The National Medical Products Administration (NMPA) in China has taken a decisive step to suspend...
Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Cleared for Clinical Trial by NMPA
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...
Hinova Pharmaceuticals Receives NMPA Approval to Test Myelofibrosis Drug Candidate HP560
Hinova Pharmaceuticals Inc. (SHA: 688302), a biopharmaceutical company based in Chengdu, has announced that it...
Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review
Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the...
Pinetree Therapeutics Strikes EGFR Degrader Deal with AstraZeneca Worth Over USD 500 Million
Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option...
Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies
Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...
Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study
Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...
Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults
Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis
China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...
ST Phi Therapeutics’ Universal Cell Therapy for Solid Tumors Gets Green Light for Clinical Trial in China
ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National...
Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities
Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key...
Hangzhou Jianjia Medical’s Arthbot Surgical Robot Receives NMPA Approval for Orthopedic Procedures
Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products...
Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China
Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...
BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...
Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors
Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...
Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...
Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...
Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies
Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally,...
Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China
Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...